Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3662 Brain Enzyme Occupancy PET Study
NCT02194491Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of clofutriben in neuropathic pain and Alzheimer's disease (AD) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Positron Emission Tomography measure: volume of distribution at Day 2, Positron Emission Tomography measure: brain time-activity curves at Day 2 and 6 more. Started Apr 2014; status: completed.
02
Drugs
clofutriben
03
Conditions
neuropathic painAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02194491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194491.